These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38779719)

  • 41. Treatment of Recurrent Refractory Pediatric Pre-B Acute Lymphoblastic Leukemia Using Inotuzumab Ozogamicin Monotherapy Resulting in CD22 Antigen Expression Loss as a Mechanism of Therapy Resistance.
    Paul MR; Wong V; Aristizabal P; Kuo DJ
    J Pediatr Hematol Oncol; 2019 Nov; 41(8):e546-e549. PubMed ID: 30807395
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study.
    Lee SH; Yoon JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Lee JW; Lee S
    Int J Hematol; 2022 Jan; 115(1):135-139. PubMed ID: 34617186
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia.
    Liu D; Zhao J; Song Y; Luo X; Yang T
    J Hematol Oncol; 2019 Feb; 12(1):15. PubMed ID: 30736842
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL.
    Kirchhoff H; Karsli U; Schoenherr C; Battmer K; Erschow S; Talbot SR; Steinemann D; Heuser M; Heidenreich O; Hilfiker-Kleiner D; Ganser A; Eder M; Scherr M
    Blood; 2021 May; 137(19):2657-2661. PubMed ID: 33512436
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL: A Phase 1 Dose-Escalation Trial.
    Kopmar NE; Quach K; Gooley TA; Martino CH; Cherian S; Percival MM; Halpern AB; Ghiuzeli CM; Oehler VG; Abkowitz JL; Walter RB; Cassaday RD
    JAMA Oncol; 2024 Jul; 10(7):961-965. PubMed ID: 38722664
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia.
    Locatelli F; Whitlock JA; Peters C; Chen-Santel C; Chia V; Dennis RM; Heym KM; Katz AJ; Kelsh MA; Sposto R; Tu H; Tuglus CA; Verma A; Vinti L; Wilkes JJ; Zubarovskaja N; Zugmaier G; von Stackelberg A; Sun W
    Leukemia; 2020 Sep; 34(9):2473-2478. PubMed ID: 32094465
    [No Abstract]   [Full Text] [Related]  

  • 47. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.
    Kantarjian H; Ravandi F; Short NJ; Huang X; Jain N; Sasaki K; Daver N; Pemmaraju N; Khoury JD; Jorgensen J; Alvarado Y; Konopleva M; Garcia-Manero G; Kadia T; Yilmaz M; Bortakhur G; Burger J; Kornblau S; Wierda W; DiNardo C; Ferrajoli A; Jacob J; Garris R; O'Brien S; Jabbour E
    Lancet Oncol; 2018 Feb; 19(2):240-248. PubMed ID: 29352703
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.
    Litzow MR; Sun Z; Mattison RJ; Paietta EM; Roberts KG; Zhang Y; Racevskis J; Lazarus HM; Rowe JM; Arber DA; Wieduwilt MJ; Liedtke M; Bergeron J; Wood BL; Zhao Y; Wu G; Chang TC; Zhang W; Pratz KW; Dinner SN; Frey N; Gore SD; Bhatnagar B; Atallah EL; Uy GL; Jeyakumar D; Lin TL; Willman CL; DeAngelo DJ; Patel SB; Elliott MA; Advani AS; Tzachanis D; Vachhani P; Bhave RR; Sharon E; Little RF; Erba HP; Stone RM; Luger SM; Mullighan CG; Tallman MS
    N Engl J Med; 2024 Jul; 391(4):320-333. PubMed ID: 39047240
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.
    Zugmaier G; Gökbuget N; Klinger M; Viardot A; Stelljes M; Neumann S; Horst HA; Marks R; Faul C; Diedrich H; Reichle A; Brüggemann M; Holland C; Schmidt M; Einsele H; Bargou RC; Topp MS
    Blood; 2015 Dec; 126(24):2578-84. PubMed ID: 26480933
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia.
    Wullenkord R; Reicherts C; Mikesch JH; Marx J; Wethmar K; Albring J; Call S; Lenz G; Stelljes M
    Ann Hematol; 2021 Feb; 100(2):587-589. PubMed ID: 32829460
    [No Abstract]   [Full Text] [Related]  

  • 51. Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia.
    Dombret H; Topp MS; Schuh AC; Wei AH; Durrant S; Bacon CL; Tran Q; Zimmerman Z; Kantarjian H
    Leuk Lymphoma; 2019 Sep; 60(9):2214-2222. PubMed ID: 30947585
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Monoclonal antibody-based therapies in the treatment of acute lymphoblastic leukemia.
    Litzow MR
    Am Soc Clin Oncol Educ Book; 2013; ():294-9. PubMed ID: 23714527
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment.
    Mejstríková E; Hrusak O; Borowitz MJ; Whitlock JA; Brethon B; Trippett TM; Zugmaier G; Gore L; von Stackelberg A; Locatelli F
    Blood Cancer J; 2017 Dec; 7(12):659. PubMed ID: 29259173
    [No Abstract]   [Full Text] [Related]  

  • 54. Safety and efficacy of blinatumomab: a real world data.
    Apel A; Ofran Y; Wolach O; Shimony S; Ram R; Levi I; Zektser M; Koren-Michowitz M
    Ann Hematol; 2020 Apr; 99(4):835-838. PubMed ID: 32076826
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antibodies: Immunoconjugates and autologous cellular therapy in acute lymphoblastic leukemia.
    Advani A
    Best Pract Res Clin Haematol; 2015; 28(2-3):116-23. PubMed ID: 26590768
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies.
    Kantarjian HM; Stein AS; Bargou RC; Grande Garcia C; Larson RA; Stelljes M; Gökbuget N; Zugmaier G; Benjamin JE; Zhang A; Jia C; Topp MS
    Cancer; 2016 Jul; 122(14):2178-85. PubMed ID: 27143254
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    Gökbuget N; Kantarjian HM; Brüggemann M; Stein AS; Bargou RC; Dombret H; Fielding AK; Heffner L; Rigal-Huguet F; Litzow M; O'Brien S; Zugmaier G; Gao S; Nagorsen D; Forman SJ; Topp MS
    Blood Adv; 2019 Oct; 3(20):3033-3037. PubMed ID: 31648325
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia.
    Thota S; Advani A
    Eur J Haematol; 2017 May; 98(5):425-434. PubMed ID: 28152223
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of blinatumomab, inotuzumab, and CAR T-cells: Which to choose and how to sequence for patients with relapsed disease.
    Curran E; O'Brien M
    Semin Hematol; 2020 Jul; 57(3):157-163. PubMed ID: 33256906
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma.
    Garrett M; Ruiz-Garcia A; Parivar K; Hee B; Boni J
    J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):211-222. PubMed ID: 30859374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.